Correction: Cysteine dioxygenase 1 is a metabolic liability for non-small cell lung cancer

Source: eLife - Category: Biomedical Science Tags: Biochemistry and Chemical Biology Cancer Biology Source Type: research

Related Links:

ConclusionTaken together, circRNAs have potential as biomarkers for the diagnosis, prognosis, and treatment of non-small cell lung cancer.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsOur results suggested that CL-pVAX-miR-143 might be a promising strategy for clinical treatment of non-small cell lung cancer, especially for advanced NSCLC with metastasis.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
Condition:   Carcinoma, Non-Small-Cell Lung Interventions:   Diagnostic Test: Tumor Imaging;   Procedure: Tumor Tissue Collection;   Procedure: Blood Sample Collection Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionsThe effect of therapy directed toward EGFR mutation or EML4 –ALK fusion gene might obscure the significant prognostic difference between M1b and M1c.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
In this study, the SPECT probe125I-Necitumumab were synthesized and evaluated for SPECT imaging of non-small cell lung cancer (NSCLC). In vivo biodistribution study indicated that125I-Necitumumab was cleared rapidly in most organs and tissues. Though the tumor expressed a relatively high level of EGFR, however SPECT images showed no obvious uptake in the tumors. Therefore, we considered that125I-Necitumumab was not suitable for EGFR-targeted NSCLC SPECT imaging.
Source: Journal of Radioanalytical and Nuclear Chemistry - Category: Nuclear Medicine Source Type: research
.
Source: Cell Cycle - Category: Cytology Authors: Source Type: research
The objective of this paper is to synthesise current knowledge on ALK rearrangement and its impact on the management of advanced NSCLC. Several inhibitors of the tyrosine kinase of ALK (crizotinib, ceritinib, alectinib) have been approved as first line therapies in patients with advanced ALK positive NSCLC, which are associated with a better median progression-free survival than conventional chemotherapy. Unfortunately, the emergence of drug resistance leads to tumor progression. In patients with oligoprogressive disease if local ablative therapy can be effected, continuing with the same ALK tyrosine kinase inhibitor is on...
Source: Revue des Maladies Respiratoires - Category: Respiratory Medicine Tags: Rev Mal Respir Source Type: research
Publication date: Available online 15 November 2019Source: Biosensors and BioelectronicsAuthor(s): Liying Zhao, Huaixia Yang, Xiaoke Zheng, Jinge Li, Lihe Jian, Weisheng Feng, Jinming KongAbstractCytokeratin fragment antigen 21–1 (CYFRA 21–1) DNA is a crucial biomarker closely associated with non-small cell lung cancer. Here, we fabricated a novel electrochemical biosensor for ultrasensitive detection of CYFRA 21–1 DNA via polysaccharide and electrochemically mediated atom transfer radical polymerization (eATRP) dual signal amplification. Specifically, thiolated peptide nucleic acid (PNA) probes at 5&prim...
Source: Biosensors and Bioelectronics - Category: Biotechnology Source Type: research
This study offers a great potential for ECL as an alternative safer radiosensitizer for increasing the RT efficiency against NSCLC. PMID: 31727206 [PubMed - as supplied by publisher]
Source: Oncology Research - Category: Cancer & Oncology Tags: Oncol Res Source Type: research
.
Source: Cell Cycle - Category: Cytology Authors: Source Type: research
More News: Biochemistry | Biology | Biomedical Science | Cancer | Cancer & Oncology | Chemistry | Lung Cancer | Non-Small Cell Lung Cancer